medigraphic.com
ISSN 2078-7170 (Electronic)

2016, Number 3

<< Back Next >>

CorSalud 2016; 8 (3)

First Iberian Meeting on Non-Valvular Structural Interventions: participant's notes

Moreno-Martínez FL

Language: Spanish
References: 18
Page: 173-176
PDF size: 274.13 Kb.


Text Extraction

Organized by the Spanish and Portuguese Societies of Cardiology, the 1st Iberian Meeting on Non-Valvular Structural Interventions was held on October 20 and 21, in Lisbon, Portugal. It was attended by more than a hundred renowned specialists from both countries, who commented on such important topics as: percutaneous treatment of paravalvular leaks, septal ablation in hypertrophic obstructive cardiomyopathy, left atrial appendage closure, renal denervation, peripheral arteriopathies, aortic coarctation, and other adult's congenital heart diseases.
Undoubtedly, these new –though not that novel- forms of treatment have invaded the Departments of Interventional Cardiology, for the sake of the patient, as part of the usual practice in developed countries; however, those with less economic resources are still waiting for their undeniable benefits, due to the high price of the devices used. Nevertheless, it is important to mention that there has raised that some of these procedures are cost-effective, such as the closure of the left atrial appendage, to prevent stroke in selected patients.


REFERENCES

  1. Reddy VY, Akehurst RL, Armstrong SO, Amorosi SL, Brereton N, Hertz DS, et al. Cost effectiveness of left atrial appendage closure with the Watchman device for atrial fibrillation patients with absolute contraindications to warfarin. Europace. 2016;18:979-86.

  2. Rodríguez León A, Moreno-Martínez FL. Nuevas fronteras para la Cardiología Intervencionista: el anciano. CorSalud [Internet]. 2016 [citado 24 Oct 2016];8:136-8. Disponible en: http://www.revcorsalud.sld.cu/index.php/cors/ar ticle/view/113/256

  3. Feldman T, Hellig F, Möllmann H. Structural heart interventions: the state of the art and beyond. EuroIntervention. 2016;12(Supl X):6.

  4. Eng L, Saw J. Percutaneous left atrial appendage closure: here to stay. J Thorac Dis. 2016;8:2420-3.

  5. Freixa X, Llull L, Gafoor S, Cruz-Gonzalez I, Shakir S, Omran H, et al. Characterization of cerebrovascular events after left atrial appendage occlusion. Am J Cardiol [Internet]. 2016 [citado 24 Oct 2016]. En prensa. DOI: http://dx.doi.org/10.1016/j.amjcard.2016.08.075

  6. Mandrola J. Left atrial appendage closure should stop now [Internet]. 2016 [citado 10 Nov 2016]. Disponible en: http://www.medscape.com/viewarticle/871678?nl id=110585_3801&src=WNL_mdplsnews_161111_m scpedit_card&uac=66187EG&spon=2&impID=123 2845&faf=1#vp_2

  7. Holmes DR, Kar S, Price MJ, Whisenant B, Sievert H, Doshi SK, et al. Prospective randomized evaluation of the Watchman left atrial appendage closure device in patients with atrial fibrillation versus long-term warfarin therapy: the PREVAIL trial. J Am Coll Cardiol. 2014;64:1-12.

  8. Pillarisetti J, Reddy YM, Gunda S, Swarup V, Lee R, Rasekh A, et al. Endocardial (Watchman) vs epicardial (Lariat) left atrial appendage exclusion devices: Understanding the differences in the location and type of leaks and their clinical implications. Heart Rhythm 2015;12:1501-7.

  9. Kim LK, Swaminathan RV, Looser P, Minutello RM, Wong SC, Bergman G, et al. Hospital volume outcomes after septal myectomy and alcohol septal ablation for treatment of obstructive hypertrophic cardiomyopathy: US Nationwide Inpatient Database, 2003-2011. JAMA Cardiol. 2016;1:324-32.

  10. Bader Y, Kimmelstiel C. Ablation or surgery for medically refractory HCM. Updating an imperfect dataset. Catheter Cardiovasc Interv. 2016;88:116-7.

  11. Veselka J, Zemánek D, Tomasov P, Duchonová R, Linhartová K. Alcohol septal ablation for obstructtive hypertrophic cardiomyopathy: ultra-low dose of alcohol (1 ml) is still effective. Heart Vessels. 2009;24:27-31.

  12. Cooper RM, Shahzad A, McShane J, Stables RH. Alcohol septal ablation for hypertrophic obstructtive cardiomyopathy: Safe and apparently efficacious but does reporting of aggregate outcomes hide less-favorable results, experienced by a substantial proportion of patients? J Invasive Cardiol. 2015;27:301-8.

  13. Lafont A, Durand E, Brasselet C, Mousseaux E, Hagege A, Desnos M. Percutaneous transluminal septal coil embolisation as an alternative to alcohol septal ablation for hypertrophic obstructive cardiomyopathy. Heart. 2005;91:92.

  14. Liu R, Qiao SB, Hu FH, Yang WX, Yuan JS, Cui JG. Long-term outcome and related predictors of alcohol septal ablation for patients with hypertrophic obstructive cardiomyopathy. Zhonghua Xin Xue Guan Bing Za Zhi. 2016;44:771-6.

  15. Kliger C, Ruiz CE. Reconsideración del cierre percutáneo de la fuga paravalvular: ¿hacia dónde vamos ahora? Rev Esp Cardiol. 2014;67:593-6.

  16. Millán X, Skaf S, Joseph L, Ruiz C, García E, Smolka G, et al. Transcatheter reduction of paravalvular leaks: a systematic review and meta-analysis. Can J Cardiol. 2015;31:260-9.

  17. Généreux P, Head SJ, Hahn R, Daneault B, Kodali S, Williams MR, et al. Paravalvular leak after transcatheter aortic valve replacement: the new Achilles’ heel? A comprehensive review of the literature. J Am Coll Cardiol. 2013;61:1125-36.

  18. Nishimura RA, Otto CM, Bonow RO, Carabello BA, Erwin JP, Guyton RA, et al. 2014 AHA/ACC Guideline for the management of patients with valvular heart disease: executive summary: A report of the American College of Cardiology/ American Heart Association Task Force on Practice Guidelines. Circulation. 2014;129:2440-92.




2020     |     www.medigraphic.com